Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01479582 | Providing Access to Cord Blood Units for Transplants | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 21, 2018 | clinicaltrials |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02538926 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 1 | Oct 22, 2018 | clinicaltrials |
| NCT02632903 | Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study | withdrawn | Phase 2 | 0 | Children's Hospital of Eastern OntarioOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 2, 2018 | clinicaltrials |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 21, 2018 | clinicaltrials |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT02204020 | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165) | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients(SAFEGUARD) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia(SAFEGUARDFP) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01639456 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01677949 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00101140 | Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 19, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Feb 14, 2017 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00967512 | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course | withdrawn | Phase 2 | 0 | Eleos, Inc.INDUSTRY | 0 | Sep 18, 2014 | clinicaltrials |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
| NCT00570999 | Palifermin After Haploidentical PBSCT(KGF Haplo Allo) | withdrawn | Phase 2 | 0 | European Society for Blood and Marrow TransplantationNETWORK | 1 | May 10, 2012 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2018source: clinicaltrials